We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+27.83%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$130M
AUM Growth
+$3.84M
Cap. Flow
-$22.7M
Cap. Flow %
-17.42%
Top 10 Hldgs %
57.06%
Holding
85
New
22
Increased
8
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.44M
2
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$1.79M
3
OTIC
Otonomy, Inc.
OTIC
+$1.71M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.7M
5
ZGNX
Zogenix, Inc.
ZGNX
+$1.21M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$7.59M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.31M
3
OCRX
Ocera Therapeutics, Inc.
OCRX
+$4.04M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.36M
5
NVDQ
Novadaq Technologies Inc.
NVDQ
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.65%
2 Financials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNVC
51
DELISTED
GenVec, Inc.
GNVC
$295K 0.23%
10,000
-10,000
-50% -$329K
APEN
52
DELISTED
Apollo Endosurgery, Inc.
APEN
$276K 0.21%
1,453
-130
-8% -$29.9K
APYX icon
53
Apyx Medical
APYX
$173M
$239K 0.18%
+100,000
New +$333K
ATNM icon
54
Actinium Pharmaceuticals
ATNM
$26.3M
$222K 0.17%
+3,000
New +$357K
TTHI
55
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$180K 0.14%
+26,410
New +$182K
NSPH
56
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$139K 0.11%
30,000
– –
CASM
57
DELISTED
CAS Medical Systems, Inc.
CASM
$134K 0.1%
+100,000
New +$144K
APTO
58
DELISTED
Aptose Biosciences, Inc.
APTO
$121K 0.09%
+50
New +$121K
CEMI
59
DELISTED
Chembio diagnostics, Inc.
CEMI
$106K 0.08%
26,287
– –
FATE icon
60
Fate Therapeutics
FATE
$286M
$99K 0.08%
20,190
-38,920
-66% -$193K
TNXP icon
61
Tonix Pharmaceuticals
TNXP
$160M
– –
0
– –
GBIM
62
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
$69K 0.05%
9,445
-1,500
-14% -$10.8K
CHEKW
63
DELISTED
Check-Cap Ltd. Series A Warrant
CHEKW
$55K 0.04%
+55,000
New +$48K
AKTX
64
Akari Therapeutics
AKTX
$13.8M
– –
-5
Closed -$211K
BLFS icon
65
BioLife Solutions
BLFS
$1.53B
– –
-116,279
Closed -$191K
GLMD icon
66
Galmed Pharmaceuticals
GLMD
$5.13M
– –
-878
Closed -$917K
NSPR icon
67
InspireMD
NSPR
$30.4M
– –
0
– -$50K
TARA icon
68
Protara Therapeutics
TARA
$220M
– –
-318
Closed -$132K
VANI icon
69
Vivani Medical
VANI
$110M
– –
-1,658
Closed -$408K
TRVN
70
DELISTED
Trevena, Inc.
TRVN
– –
-448
Closed -$1.67M
ACER
71
DELISTED
Acer Therapeutics Inc
ACER
$0 ﹤0.01%
+6
New +$368
BSTC
72
DELISTED
BioSpecifics Technologies Corp.
BSTC
– –
-33,466
Closed -$1.29M
IPCI
73
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-27,926
Closed -$631K
OCRX
74
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-634,893
Closed -$4.04M
UPI
75
DELISTED
UROPLASTY INC-NEW
UPI
– –
-486,062
Closed -$1M
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, DAFNA Capital Management held 85 positions worth $130M, up 3% from $126M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

DAFNA Capital Management withdrew a net $22.7M in Q1 2015, closing 13 positions and reducing 24 holdings. Its most notable exit was Ocera Therapeutics, Inc., an estimated $4.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 60% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Applied Genetic Technologies Corporation worth $2.19M.

  • DAFNA Capital Management's largest Q1 2015 buy was Applied Genetic Technologies Corporation: 109,323 shares worth $2.19M.
  • DAFNA Capital Management added most to Rigel Pharmaceuticals in Q1 2015, an estimated $989K increase.
  • DAFNA Capital Management's biggest Q1 2015 reduction was PHARMACYCLICS INC, cutting an estimated $7.59M.
  • DAFNA Capital Management fully exited Ocera Therapeutics, Inc. in Q1 2015, selling an estimated $4.04M.
  • DAFNA Capital Management's ten largest holdings make up 57% of its $130M portfolio in Q1 2015.
  • DAFNA Capital Management opened 22 new positions and closed 13 in Q1 2015.
  • DAFNA Capital Management's portfolio value rose 3% quarter-over-quarter to $130M.

Based on DAFNA Capital Management's 13F filing for Q1 2015, filed 15 May 2015.